S. Ohlman

Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Peter Charles Taylor, Philip J. Mease, Kurt de Vlam, Shephard Mpofu et autres

OBJECTIVES: To evaluate the efficacy and safety of izokibep, a small protein therapeutic designed to inhibit interleukin-17A, in patients with active psoriatic arthritis (PsA) over 46 weeks. METHODS: This phase 2, multicentre, placebo-controlled study randomised adult patients with active PsA 1:1:1 to …

gb, us, be, de, se, cz (code pays fourni par la source)

Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment

Sascha Gerdes, Petra Staubach, Thomas Dirschka, Dieter Wetzel et autres

BACKGROUND: Monoclonal antibodies to interleukin (IL)-17 have shown strong efficacy in patients with psoriasis. Izokibep is a unique IL-17A inhibitor with a small molecular size and favourable distribution to sites of inflammation. OBJECTIVES: To evaluate the dose response, efficacy and safety of …

de, se (code pays fourni par la source)

A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares

Kenneth G. Saag, Puja P. Khanna, Robert T. Keenan, S. Ohlman et autres

OBJECTIVE: To evaluate the efficacy and safety of anakinra compared to triamcinolone in the treatment of gout flares. METHODS: Patients for whom nonsteroidal antiinflammatory drugs and colchicine were not suitable treatments were enrolled in this multicenter, randomized, double-blind study with follow-up for …

us, se, ch (code pays fourni par la source)

THU0409 A RANDOMIZED, PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF ANAKINRA IN DIFFICULT-TO-TREAT ACUTE GOUTY ARTHRITIS: THE ANAGO STUDY

Kenneth G. Saag, A. So, Param Pal Khanna, Robert T. Keenan et autres

us, ch, se (code pays fourni par la source)

AB1059 A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ANAKINRA IN PATIENTS WITH STILL´S DISEASE

Laura Eve Schanberg, Peter Andrija Nigrovic, Adam James Cooper, Walter Winn Chatham et autres

us, se, it (code pays fourni par la source)

THU0439 EFFICACY AND SAFETY OF ANAKINRA IN THE TREATMENT OF RECURRENT GOUT FLARES: RESULTS FROM THE EXTENSION PHASE OF THE ANAGO STUDY

Kenneth G. Saag, Param Pal Khanna, Robert T. Keenan, S. Ohlman et autres

us, se, ch (code pays fourni par la source)

Anakinra in children and adults with Still’s disease

Sebastiaan J. Vastert, Yvan Jamilloux, Pierre Quartier, S. Ohlman et autres

Systemic juvenile idiopathic arthritis and adult-onset Still's disease are rare autoinflammatory disorders with common features, supporting the recognition of these being one disease-Still's disease-with different ages of onset. Anakinra was recently approved by the European Medicines Agency for Still's disease. In this …

nl, fr, se, it (code pays fourni par la source)

NXX-066 IN ALZHEIMER PATIENTS: A BRIDGING STUDY

Neal R. Cutler, Gary H. Friday, Lloyd Peter Haskell, Stanford S. Jhee et autres

us (code pays fourni par la source)

157. NXX-066 in patients with Alzheimer's disease: A bridging study

Neal R. Cutler, Gary H. Friday, J.J. Sramek, Lloyd Peter Haskell et autres

Analysis of Azathioprine and 6-Mercaptopurine in Plasma in Renal Transplant Recipients After Administration with Oral Azathioprine

Freidoun Albertioni, Bo Pettersson, S. Ohlman, C. Peterson

Studies on the pharmacokinetics of azathioprine (AZA) and its main metabolite, 6-mercaptopurine (6-MP) in patients treated with oral AZA, such as renal transplant recipients, require an analytical method with a high sensitivity. Since the substances differ substantially in their physicochemical properties, it …

se (code pays fourni par la source)

Day‐to‐day variability in azathioprine pharmacokinetics in renal transplant recipients

S. Ohlman, Freidoun Albertioni, C. Peterson

The intraindividual and the interindividual variability in the pharmacokinetics of azathioprine (Aza) and its main metabolite 6-mercaptopurine (6-MP) were investigated in 10 renal transplant patients on 2 consecutive days, after repeated oral doses of Aza. On the 1st study, the dose-adjusted Aza …

se (code pays fourni par la source)

Pharmacokinetics of 15-deoxyspergualin studied in renal transplant patients receiving the drug during graft rejection

S. Ohlman, Harald ZILG, Fritz Schindel, Anna Lindholm Olinder

The pharmacokinetics of the novel immunosuppressant 15-deoxyspergualin (DSG) were studied in five renal transplant patients who participated in a dose-finding study for the treatment of renal graft rejection. DSG, in a dose of 4 or 6 mg/kg per day, was given in …

se, de (code pays fourni par la source)